Beta Blockers & Angiotensin Receptor Blockers in Bicuspid Aortic Valve

Status Terminated

Clinical Trial Summary

The purpose of this study is to determine whether long-term treatment with a beta-blocker (BB) such as atenolol and/or an angiotensin receptor blocker (ARB) such as telmisartan, given to adult patients with bicuspid aortic valve (BAV) disease (aortopathy) reduces the widening (dilatation) of the aorta from its baseline size.

Clinical Trial Description

Bicuspid aortic valve (BAV) is the most common congenital heart disease lesion with an estimated 280 000 to 560 000 people affected in the Canada. Dilatation of the ascending aorta is a common feature in patients with BAV and is a result of inherent vascular abnormalities with superimposed effects of age and acquired cardiovascular risk factors. Severe aortic dilatation (> 50mm) leads to aortic dissection and premature death.

Histopathological studies of the aortas in patients with BAVs report similar findings to that of patients with Marfan syndrome. Beta Blocker (BB) therapy and more recently, Angiotensin Receptor Blocker (ARB) therapy, have been shown to decrease to rate of aortic dilatation and be of benefit to patients with Marfan syndrome. There is no such data however in patients with BAV and aortopathy.

Within the context of a randomized clinical trial, the investigators proposed to test the hypothesis that BB or ARB will reduce the rate of progressive aortic dilatation in adults with BAVs and ascending aortopathy as compared to placebo.

Design: Multicentre, randomized, double-blind, placebo-controlled, trial of adult patients with bicuspid aortic valve aortopathy. Patients who are eligible to take either study medication will be randomly allocated to participate in either the BB (atenolol) vs. placebo arm, or the ARB (telmisartan) vs. placebo arm. Patients who are ineligible for the BB arm will be assigned to the ARB vs. placebo arm and patients who are ineligible for the ARB arm will be assigned to the BB vs. placebo arm. Within each arm, all participants will be randomized to take either placebo or active medication. The atenolol arm will be up-titrated to100mg/day and the telmisartan arm will be up-titrated to 80 mg/day, or to the maximum tolerated dose. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01202721
Study type	Interventional
Source	Hamilton Health Sciences Corporation
Contact
Status	Terminated
Phase	Phase 3
Start date	June 2011
Completion date	November 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05490303` - HeartGuide: Preliminary Study	N/A
Completed	`NCT05070819` - Atrial Natriuretic Peptide in Assessing Fluid Status	N/A
Not yet recruiting	`NCT04538469` - Absent Visitors: The Wider Implications of COVID-19 on Non-COVID Cardiothoracic ICU Patients, Relatives and Staff
Not yet recruiting	`NCT04511403` - Prevalence of Oral Mucosal Alterations In a Sample of Egyptian Patients With Cardiovascular Diseases: A Hospital- Based Cross-Sectional Study
Completed	`NCT02697760` - The CZT Dynamic Myocardial Perfusion Imaging
Terminated	`NCT05157568` - Pilot Randomized Clinical Trial of Live-streamed Cardiovascular Rehabilitation	N/A
Not yet recruiting	`NCT04160845` - Non-invasive Forehead Skin Temperature in Cardiac Surgery
Completed	`NCT04500912` - Comparison of the Supraflex Cruz 60 Micron Versus the Ultimaster Tansei 80 Micron in HBR PCI Population	N/A
Not yet recruiting	`NCT06438159` - Impact of Mindfulness-Based Stress Reduction Meditation Practice on Patients After Cardiac Rehabilitation.	N/A
Recruiting	`NCT06154473` - Assessment of Patients Undergoing Cardiac Surgery and Admitted to the Intensive Care Unit
Not yet recruiting	`NCT05877755` - Validation of Multi-contrast, High-resolution Cardiac Magnetic Resonance Imaging	N/A
Completed	`NCT03394859` - Electronic Medical Records and Genomics (eMERGE) Phase III
Recruiting	`NCT05055830` - Opportunistic PK/PD Trial in Critically Ill Children (OPTIC)
Recruiting	`NCT04374799` - Heparin vs Placebo for Cardiac Catheterization	Phase 3
Completed	`NCT03174106` - Longterm Follow-up of Cardiac Patients With an Smartphone-Application	N/A
Recruiting	`NCT05531253` - Respired Gases in Patients Post Cardiac Surgery
Recruiting	`NCT04609228` - Cardiac Surgery Outcomes in Blood-transfusion Acceptors and no Acceptors
Recruiting	`NCT06149143` - Cardiac Performance System Data Collection Study - Minnesota
Recruiting	`NCT05725655` - Hot Water Immersion After Myocardial Infarction	N/A
Recruiting	`NCT06073509` - Atrial Fibrillation and Other Cardiac Arrhythmias and Diseases After Radiotherapy for Breast Cancer : Watch Your HeaRT

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Beta Blockers and Angiotensin Receptor Blockers in Bicuspid Aortic Valve Disease Aortopathy (BAV Study) — BAV

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms